disputing online gambling charges reddit
NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Lilium N.V. (OTC Other: LILM). Shareholders who purchased shares of LILM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lilium-n-v-loss-submission-form/?id=113438&from=3 CLASS PERIOD: June 11, 2024 to November 3, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants overstated the progress of the Company’s fundraising activities; (2) defendants overstated the likelihood and/or feasibility of obtaining sufficient funding to continue operations; (3) defendants failed to sufficiently disclose the imminent insolvency of the Company and its subsidiaries; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. DEADLINE: January 6, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/lilium-n-v-loss-submission-form/?id=113438&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of LILM during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is January 6, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: dg@securitiesclasslaw.com Phone: (646) 453-8903Zimbabwe: Yadah, Caps Utd Clash Over Shandirwa
MIAMI — A Miami-Dade traffic hearing officer dismissed Miami Dolphins star Tyreek Hill’s citations after the Miami-Dade Police officer who cited him failed to show up in court, in an incident that led to Hill getting handcuffed and pinned to the ground outside Hard Rock Stadium. Miami-Dade Police issued Hill a $179 careless driving violation and a $129 seat belt violation during a Sept. 8 traffic stop hours before the Dolphins’ season opener against the Jacksonville Jaguars at the stadium. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.NoneDwarfed by China in shipbuilding, US looks to build its defense base to fend off war
By Michelle Marchante, Miami Herald (TNS) MIAMI — As her students finished their online exam, Arlet Lara got up to make a cafe con leche . Her 16-year-old son found her on the kitchen floor. First, he called Dad in a panic. Then 911. “I had a stroke and my life made a 180-degree turn,” Lara told the Miami Herald, recalling the medical scare she experienced in May 2020 in the early months of the COVID pandemic. “The stroke affected my left side of the body,” the North Miami woman and former high school math teacher said. Lara, an avid runner and gym goer, couldn’t even walk. “It was hard,” the 50-year-old mom said. After years of rehabilitation therapy and a foot surgery, Lara can walk again. But she still struggles with moving. This summer, she became the first patient in South Florida to get an implant of a new and only FDA-approved nerve stimulation device designed to help ischemic stroke survivors regain movement in their arms and hands. This first procedure was at Jackson Memorial Hospital in Miami. Lara’s rehab was at at the Christine E. Lynn Rehabilitation Center for The Miami Project to Cure Paralysis, part of a partnership between Jackson Health System and UHealth. Every year, thousands in the United States have a stroke , with one occurring every 40 seconds, according to the U.S. Centers for Disease Control and Prevention. The majority of strokes are ischemic, often caused by blood clots that obstruct blood flow to the brain. For survivors, most of whom are left with some level of disability, the Vivistim Paired VNS System, the device implanted in Lara’s chest, could be a game changer in recovery, said Dr. Robert Starke, a UHealth neurosurgeon and interventional neuroradiologist. He also serves as co-director of endovascular neurosurgery at Jackson Memorial Hospital, part of Miami-Dade’s public hospital system. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant designed to help stroke survivors regain function in their arms, goes through exercises while her therapist activates the device during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA- approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) The Vivistim Paired VNS System is a small pacemaker-like device implanted in the upper chest and neck area. Patients can go home the same day. The U.S. Food and Drug Administration approved the stroke rehabilitation system in 2021 to be used alongside post-ischemic stroke rehabilitation therapy to treat moderate to severe mobility issues in hands and arms. Lara’s occupational therapist can activate the device during rehabilitation sessions to electrically stimulate the vagus nerve, which runs from the brain down to the abdomen and regulates various parts of the body’s nervous system. The electrical stimulation rewires the brain to improve a stroke survivor’s ability to move their arms and hands. Lara also has a magnet she can use to activate the device when she wants to practice at home. Her therapy consists of repetitive tasks, including coloring, pinching cubes and grabbing and releasing cylindrical shapes. After several weeks of rehabilitation therapy with the device, Lara has seen improvement. “Little by little, I’m noticing that my hand is getting stronger. I am already able to brush my teeth with the left hand,” she told the Miami Herald in September. Since then, Lara has finished the initial six-week Vivitism therapy program, and is continuing to use the device in her rehabilitation therapy. She continues to improve and can now eat better with her left hand and can brush her hair with less difficulty, according to her occupational therapist, Neil Batungbakal. Lara learned about the device through an online group for stroke survivors and contacted the company to inquire. She then connected them with her Jackson medical team. Now a year later, the device is available to Jackson patients. So far, four patients have received the implant at Jackson. Related Articles Starke sees the device as an opportunity to help bring survivors one step closer to regaining full mobility. Strokes are a leading cause of disability worldwide. While most stroke survivors can usually recover some function through treatment and rehabilitation, they tend to hit a “major plateau” after the first six months of recovery, he said. Vivistim, when paired with rehabilitation therapy, could change that. Jackson Health said results of a clinical trial published in the peer-reviewed medical journal The Lancet in 2021 showed that the device, “when paired with high-repetition, task-specific occupational or physical therapy, helps generate two to three times more hand and arm function for stroke survivors than rehabilitation therapy alone.” The device has even shown to benefit patients 20 years from their original stroke, according to Starke. “So now a lot of these patients that had strokes 10-15 years ago that thought that they would never be able to use their arm in any sort of real functional way are now able to have a real meaningful function, which is pretty tremendous,” Starke said. Vivistim’s vagus-nerve stimulation technology was developed by researchers at the University of Texas at Dallas’ Texas Biomedical Device Center and is being sold commercially by Austin-based MicroTransponder, a company started by university graduates. Similar devices are used to treat epilepsy and depression . For Lara, the device is a new tool to help her recovery journey. “Everything becomes a challenge so we are working with small things every day because I want to get back as many functions as possible,” Lara said. Patients interested in Vivistim should speak with their doctor to check their eligibility. The FDA said patients should make sure to discuss any prior medical history, including concurrent forms of brain stimulation, current diathermy treatment, previous brain surgery, depression, respiratory diseases and disorders such as asthma, and cardiac abnormalities. “Adverse events included but were not limited to dysphonia (difficulty speaking), bruising, falling, general hoarseness, general pain, hoarseness after surgery, low mood, muscle pain, fracture, headache, rash, dizziness, throat irritation, urinary tract infection and fatigue,” the FDA said. MicroTransponder says the device is “covered by Medicare, Medicaid, and private insurance with prior authorization on a case-by-case basis.” To learn more about the device, visit vivistim.com. ©2024 Miami Herald. Visit at miamiherald.com. Distributed by Tribune Content Agency, LLC.Man City collapse ‘difficult to swallow’ – Pep GuardiolaUS stock futures drift lower as Wall St ends record run before nonfarm payrolls
ORCHARD PARK — Kyle Juszczyk was inches from the goal line. Matt Milano’s arms were wrapped around his waist, but his legs were still pumping. And then Taylor Rapp made a quick right jab at the ball, jarring it from Juszczyk’s grasp as it rolled to Christian Benford’s waiting hands. Juszczyk’s fumble came on the first drive of the second half with the San Francisco 49ers trailing 21-3. But the 49ers moved the ball during the first half, started the second with a 60-yard kickoff return and could sniff the end zone. Instead they came away with nothing and lost 35-10. It wasn’t a turnover, Buffalo Bills defensive coordinator Bobby Babich insists. It was a takeaway and the Bills have created one in every game this season, seemingly always at the right moment. The Bills are second in takeaways (one behind the Pittsburgh Steelers) and 11 of their 24 forced turnovers have come on their side of the field. It might seem like fool’s gold, luck or a dangerous way to play. But in a flukey statistic, the Bills are consistently among the NFL leaders under coach Sean McDermott. In fact, the Bills have 212 takeaways since 2017 and no other team in the league has 200. The Bills have finished in the top-10 in takeaways each year since 2018, finishing in the top-four since 2021. Meanwhile, Buffalo’s 130 interceptions since 2017 are one behind the New England Patriots, while finishing no worse than eighth since McDermott took over. “You get what you emphasize,” Babich said. “... I think what happens is kind of when you walk in this door, that standard is kind of like a cloud just sitting over the top of us of, they know, even in practice, as simple as it is, if we don't take the ball away, we make sure we understand that that's not good enough.” The #Bills won their fifth AFC East championship in a row, while the #Sabres followed three wins with four losses to remain predictably unpredictable. @billhoppe.bsky.social dig into it all. fireside.fm/episode/sMvb... Emphasis or not, it’s up to the players to force turnovers and a large piece of that comes down to the type of players the Bills place in their defense. Both McDermott and general manager Brandon Beane have spoken at length about finding football players with instincts rather than eye-popping workout results. When the Bills can’t draft those players, they find them in free agency or in the draft. Rapp had 10 takeaways in four seasons with the Los Angeles Rams, while cornerback Rasul Douglas had 11 in the 2 1⁄2 seasons with the Green Bay Packers before being traded to the Bills last season. There are some instincts that cannot be taught, but the Bills have been able to develop and strengthen instincts for players who are in the system for a longer period of time. The Bills teach players to be aware of the ball, to not just make a tackle, but swipe at the ball while doing so. In a scenario like Rapp’s forced fumble, the Bills teach players that the first man’s responsibility is to make a tackle and the second man goes for the ball. “I'd say for me, like, as far as, like, my mind being on the ball more often than it was when I was a younger player,” said Bills cornerback Taron Johnson, who has four forced fumbles in the last two seasons after recording four in his first five years combined. “So I'm looking for opportunities, more opportunities to take the ball away than I was when I was younger.” Turnover consistency has been steady despite the Bills slightly tweaking their defensive philosophy in recent years. During McDermott’s first five seasons, the Bills blitzed on more than 30% of passing plays and that number has dropped to 21.5% over the last three seasons, including 17.5% this year under Babich, the third-lowest rate in the league. Early in McDermott’s tenure, the Bills were one of the best teams in the league at disguising coverages, changing what the quarterback was seeing pre-snap compared to when he actually had the ball. They still do their share of disguising, but now the Bills try to attack the quarterback with four rushers and play a soft zone in the secondary until opponents cross midfield. “We always talk about rush and coverage working together,” Bills linebacker Terrel Bernard told GNN Sports. “So we do our part on the back end of disguising the picture or studying routes and understanding concepts that makes them hold it a little bit, which in turn gives the D-line a better chance to get back there and affect them. When that happens, then the ball comes to us.” If the Bills can affect the quarterback with four rushers, not only can they prevent more big plays, but more areas in the secondary are covered. But it’s not a simplistic defense, . Being comfortable with the different communications and disguises takes time. The Bills had the same safety pairing for most of McDermott’s first seven seasons and the system has largely been the same for his entire run. Even without Jordan Poyer and ) the Bills still had plenty of experience on defense. Fifteen players have been with the Bills at least three seasons, with eight having at least four. “The more comfortable you are in the system, the better you can disguise because you know your issues in certain defenses and certain coverages,” said Bills practice squad quarterback Mike White, who played against the Bills for three seasons with the Dolphins and Jets. “But it's interesting. You know what they're going to play, they know you know what they're going to play, but they still do a good job of disguising and get you to just second-guess for a minute.” It’s a brand of defense many teams have adopted in the NFL, which is why rushing yards are up and passing yards are down. The Bills have given up the fewest 30-yard passes (79) and the fewest passes of 50 yards or more (14) since McDermott became coach. “That’s part of our philosophy and who we are,” said Bernard, who has nine takeaways in 26 games as a starter. “I think that standard has just been set since before I got here. So buying into that and believing that and I think everybody on this defense believes in that.” WR Keon Coleman (wrist) and S Taylor Rapp (neck/shoulder) wore red non-contact jerseys and were limited in practice Thursday. ... TE Dalton Kincaid (knee), TE Quintin Morris (shoulder/groin) and WR Curtis Samuel (foot) were also limited.
PHILADELPHIA — Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia, said he was “shocked” by President-elect Donald Trump’s choice of anti-vaccine activist and former presidential candidate Robert F. Kennedy Jr. to run the Department of Health and Human Services. Calling Kennedy an “agent of chaos in the vaccination world,” Offit asserted that under Kennedy, a vaccine denier , “children could suffer that chaos.” Trump announced Kennedy’s selection last week. The move follows Kennedy’s decision in August to endorse Trump and withdraw his own independent candidacy in key states, including Pennsylvania. “I’m going to let him go wild on health,” Trump said of Kennedy at an October rally in New York. “I’m going to let him go wild on food. I’m going to let him go wild on medicines.” For years, Kennedy, a conspiracy theorist, has said that vaccines cause autism , a falsehood that has been disproven multiple times by dozens of scientists around the world. “RFK Jr. is a dangerous man,” Offit said. “This decision is completely and utterly depressing.” Offit and Kennedy connected 20 years ago when Kennedy called to ask whether thimerosal , a compound safely used as a preservative in vaccines, caused cancer. “I assured him it was untrue — that it had been removed from all vaccines by 2001,” said Offit, coinventor of the rotavirus vaccine, which attacks the virus that can lead to fatal diarrhea in children. But Kennedy disregarded Offit’s expertise, and has been blaming vaccines for autism ever since. “RFK Jr. has become a science denialist,” Offit said. “If you present him with science, he’ll ignore it if it goes against a bias he has.” Kennedy’s team did not comment after receiving a list of questions, as well as Offit’s statements. As head of HHS, Kennedy wouldn’t have direct authority to ban vaccines, according to reporting by The Hill . But Offit and others say he’ll stay have powerful influence over the agencies that regulate vaccines, with the authority to reduce funding, or remove protections vaccine makers usually have. Kennedy has promised to “ Make America Healthy Again ,” imitating Trump’s slogan. Aside from his pledge to “expose the flaws in vaccine science,” Kennedy said he’d battle chronic disease in America by “breaking the stranglehold of the processed food lobby,” and working to “clear out corruption” at America’s health agencies, which could involve eliminating entire departments. Kennedy has also proposed combating the chronic disease epidemic by addressing the root causes such as poor diet, environmental toxins, and inadequate healthcare. He’s also called to reduce harmful chemicals and toxins from America’s food, water, and air. In October, Kennedy said in a post on the social platform X the he won’t “take anyone’s vaccines away from them. I just want to be sure every American knows the safety profile, the risk profile, and the efficacy of each vaccine. That’s it.” Offit doesn’t find reassurance in this promise, arguing that Kennedy’s selection will help amplify anti-vaccine rhetoric. “Just the mere fact he’s being considered for this job will validate some parents’ fears about vaccinations. Even now in kindergarten, measles and whooping cough vaccines are being refused by parents in some cases.” Kennedy has spread other health misinformation , saying: the use of vaccinations is akin to the Holocaust ; the coronavirus vaccine is the “ deadliest” created by man; drinking water can change children’s gender identity ; fluoride in water can lower IQ ; the coronavirus was “ethnically targeted” to prevent Jews and Chinese people from succumbing to COVID-19; WiFi causes cancer; drinking raw milk, which can contain E. coli and listeria, should be encouraged ; and antidepressants are to blame for school shootings. Kennedy will sometimes further confuse people by denying saying things he has. For example, he recently said he’s “never been anti-vaccine,” and that “no vaccine” is safe and effective. But last November, FactCheck.org , part of the Annenberg Public Policy Center at the University of Pennsylvania, said that’s incorrect . The nonprofit discovered a Lex Fridman podcast Kennedy had done in July 2023 in which he said, “There’s no vaccine that is, you know, safe and effective.” Offit said he can’t understand Kennedy’s nomination. “Why would you put this person in charge of agencies based on science? He makes things up. He’s just a liar.” ©2024 The Philadelphia Inquirer, LLC. Visit at inquirer.com . Distributed by Tribune Content Agency, LLC.
By Michelle Marchante, Miami Herald (TNS) MIAMI — As her students finished their online exam, Arlet Lara got up to make a cafe con leche . Her 16-year-old son found her on the kitchen floor. First, he called Dad in a panic. Then 911. “I had a stroke and my life made a 180-degree turn,” Lara told the Miami Herald, recalling the medical scare she experienced in May 2020 in the early months of the COVID pandemic. “The stroke affected my left side of the body,” the North Miami woman and former high school math teacher said. Lara, an avid runner and gym goer, couldn’t even walk. “It was hard,” the 50-year-old mom said. After years of rehabilitation therapy and a foot surgery, Lara can walk again. But she still struggles with moving. This summer, she became the first patient in South Florida to get an implant of a new and only FDA-approved nerve stimulation device designed to help ischemic stroke survivors regain movement in their arms and hands. This first procedure was at Jackson Memorial Hospital in Miami. Lara’s rehab was at at the Christine E. Lynn Rehabilitation Center for The Miami Project to Cure Paralysis, part of a partnership between Jackson Health System and UHealth. Every year, thousands in the United States have a stroke , with one occurring every 40 seconds, according to the U.S. Centers for Disease Control and Prevention. The majority of strokes are ischemic, often caused by blood clots that obstruct blood flow to the brain. For survivors, most of whom are left with some level of disability, the Vivistim Paired VNS System, the device implanted in Lara’s chest, could be a game changer in recovery, said Dr. Robert Starke, a UHealth neurosurgeon and interventional neuroradiologist. He also serves as co-director of endovascular neurosurgery at Jackson Memorial Hospital, part of Miami-Dade’s public hospital system. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant designed to help stroke survivors regain function in their arms, goes through exercises while her therapist activates the device during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. The activation works as positive reinforcement to her muscles when she completes the exercise correctly. (Alie Skowronski/Miami Herald/TNS) Arlet Lara, the first patient in South Florida to get an FDA- approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, right, runs into her rehabilitation neurology physician Dr. Gemayaret Alvarez, before her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The implant is designed to help stroke survivors regain function in their arms. (Alie Skowronski/Miami Herald/TNS) The Vivistim Paired VNS System is a small pacemaker-like device implanted in the upper chest and neck area. Patients can go home the same day. The U.S. Food and Drug Administration approved the stroke rehabilitation system in 2021 to be used alongside post-ischemic stroke rehabilitation therapy to treat moderate to severe mobility issues in hands and arms. Lara’s occupational therapist can activate the device during rehabilitation sessions to electrically stimulate the vagus nerve, which runs from the brain down to the abdomen and regulates various parts of the body’s nervous system. The electrical stimulation rewires the brain to improve a stroke survivor’s ability to move their arms and hands. Lara also has a magnet she can use to activate the device when she wants to practice at home. Her therapy consists of repetitive tasks, including coloring, pinching cubes and grabbing and releasing cylindrical shapes. After several weeks of rehabilitation therapy with the device, Lara has seen improvement. “Little by little, I’m noticing that my hand is getting stronger. I am already able to brush my teeth with the left hand,” she told the Miami Herald in September. Since then, Lara has finished the initial six-week Vivitism therapy program, and is continuing to use the device in her rehabilitation therapy. She continues to improve and can now eat better with her left hand and can brush her hair with less difficulty, according to her occupational therapist, Neil Batungbakal. Lara learned about the device through an online group for stroke survivors and contacted the company to inquire. She then connected them with her Jackson medical team. Now a year later, the device is available to Jackson patients. So far, four patients have received the implant at Jackson. Related Articles Starke sees the device as an opportunity to help bring survivors one step closer to regaining full mobility. Strokes are a leading cause of disability worldwide. While most stroke survivors can usually recover some function through treatment and rehabilitation, they tend to hit a “major plateau” after the first six months of recovery, he said. Vivistim, when paired with rehabilitation therapy, could change that. Jackson Health said results of a clinical trial published in the peer-reviewed medical journal The Lancet in 2021 showed that the device, “when paired with high-repetition, task-specific occupational or physical therapy, helps generate two to three times more hand and arm function for stroke survivors than rehabilitation therapy alone.” The device has even shown to benefit patients 20 years from their original stroke, according to Starke. “So now a lot of these patients that had strokes 10-15 years ago that thought that they would never be able to use their arm in any sort of real functional way are now able to have a real meaningful function, which is pretty tremendous,” Starke said. Vivistim’s vagus-nerve stimulation technology was developed by researchers at the University of Texas at Dallas’ Texas Biomedical Device Center and is being sold commercially by Austin-based MicroTransponder, a company started by university graduates. Similar devices are used to treat epilepsy and depression . For Lara, the device is a new tool to help her recovery journey. “Everything becomes a challenge so we are working with small things every day because I want to get back as many functions as possible,” Lara said. Patients interested in Vivistim should speak with their doctor to check their eligibility. The FDA said patients should make sure to discuss any prior medical history, including concurrent forms of brain stimulation, current diathermy treatment, previous brain surgery, depression, respiratory diseases and disorders such as asthma, and cardiac abnormalities. “Adverse events included but were not limited to dysphonia (difficulty speaking), bruising, falling, general hoarseness, general pain, hoarseness after surgery, low mood, muscle pain, fracture, headache, rash, dizziness, throat irritation, urinary tract infection and fatigue,” the FDA said. MicroTransponder says the device is “covered by Medicare, Medicaid, and private insurance with prior authorization on a case-by-case basis.” To learn more about the device, visit vivistim.com. ©2024 Miami Herald. Visit at miamiherald.com. Distributed by Tribune Content Agency, LLC.
Sporting 1 Arsenal 5: Gunners run riot in Champions League and become first team this term to beat giants in 90 minutes
The Detroit Lions will play without two high draft picks in rookie cornerbacks Terrion Arnold and Ennis Rakestraw Jr. while possibly getting back veteran Emmanuel Moseley against the host Indianapolis Colts on Sunday. Arnold was downgraded Saturday from questionable to out because of a groin injury. He was limited at practice on Thursday and participated in a full practice on Friday. The Lions drafted Arnold with the 24th overall pick of the 2024 NFL Draft out of Alabama. Arnold, 21, has started all 10 games and has 38 tackles and six passes defended. Rakestraw (hamstring) was placed on injured reserve after not practicing all week. He already had been ruled out for Sunday's game. Detroit picked Rakestraw in the second round (61st overall) out of Missouri. He has played in eight games and has six tackles. Rakestraw, 22, has played on 46 defensive snaps (8 percent) and 95 special teams snaps (42 percent). Moseley had full practice sessions all week and was activated from injured reserve on Saturday but was listed as questionable for Sunday. The 28-year-old is in his second season with Detroit and appeared in one game last season before going on IR in October 2023. He was placed on IR on Aug. 27 with a designation to return. Moseley played from 2018-22 for the San Francisco 49ers and had 162 tackles, four interceptions -- one returned for a touchdown -- and 33 passes defensed in 46 games (33 starts). Detroit elevated linebacker David Long on Saturday for game day. Long, 28, signed with the practice squad on Tuesday after the Miami Dolphins released him on Nov. 13. He had started six of eight games for the Dolphins this season and had 38 tackles. In other Lions news, the NFL fined wide receiver Jameson Williams $19,697 for unsportsmanlike conduct for making an obscene gesture during a touchdown celebration in last Sunday's 52-6 home win over the Jacksonville Jaguars, the NFL Network reported Saturday. Williams, 23, scored on a 65-yard pass from Jared Goff with 12:55 remaining in the third quarter. --Field Level Media10-man Barcelona concedes two late goals in draw at Celta Vigo
DUBAI, United Arab Emirates, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Rexas Finance (RXS) solidifies its position as a leader in real-world asset (RWA) tokenization, wrapping up Stage 6 of its presale ahead of schedule due to overwhelming investor interest. With $12.2 million raised so far, the presale demonstrates the project's broad appeal. The seventh stage is now live, priced at $0.09 per token, marking a threefold increase from Stage 1. Investors at this stage can expect a 2.22x return on launch, highlighting the token's potential. As the crypto market shifts towards innovative applications, Rexas Finance is bridging the gap between blockchain technology and traditional investments. Transforming Investments Through RWA Tokenization Rexas Finance is redefining investment by tokenizing real-world assets such as real estate, commodities, and art. This platform simplifies global ownership, allowing users to buy fractional or full shares in high-value assets with a single click. Investors can now own a portion of a luxury property in Europe or a piece of gold bullion from the comfort of their homes, earning returns proportionate to their stake. By tokenizing assets on the blockchain, Rexas Finance eliminates traditional barriers like high entry costs and illiquidity. The global real estate market, valued at over $300 trillion, and the $121 trillion commodities market are now within reach for all investors. This approach not only democratizes access but also enhances market liquidity, paving the way for seamless trading and ownership transfers. The Rexas Token Builder empowers users to tokenize their assets independently, creating digital tokens that represent ownership shares. For those seeking funding for their projects, the Rexas Launchpad facilitates fundraising by connecting innovative ideas with investors. The QuickMint Bot and AI-powered tools further streamline tokenization, offering simple, accessible solutions even for blockchain newcomers. The Unstoppable Growth of RXS Rexas Finance's presale is a testament to its growing market traction. The project has prioritized public participation over traditional venture capital, ensuring widespread access to this revolutionary platform. All six presale stages sold out swiftly, raising $12.2 million and reflecting strong community support. The seventh stage, priced at $0.09, continues to attract attention, as early investors anticipate significant returns. The RXS token is ERC-20-based, with a total supply of one billion tokens distributed strategically to ensure liquidity and growth: 42.5% for presale, 22.5% for staking, 15% for liquidity, and smaller allocations for marketing, treasury, and partnerships. Rexas Finance is also driving engagement through its $1 million giveaway, where 20 participants will win $50,000 each. Users can increase their chances by completing tasks, referring friends, and submitting their ERC20 wallet addresses. A Growing Ecosystem with Real-World Impact Beyond tokenization, Rexas Finance builds a comprehensive ecosystem for RWA management. Its Rexas Estate initiative targets the lucrative real estate market, making properties globally accessible. Meanwhile, its AI tools and QuickMint Bot offer unmatched convenience, removing barriers to blockchain adoption. The platform's listing on CoinMarketCap and CoinGecko adds visibility and credibility, attracting a broader investor base. Being CertiK-audited further assures users of the security and reliability of RXS, bolstering confidence in its smart contracts. Rexas Finance also plans to launch on three Tier 1 exchanges, ensuring accessibility for global investors and driving liquidity. As blockchain adoption grows, Rexas Finance is positioned to capitalize on the trend, putting nearly every imaginable real-world asset on blockchain networks. Final Thoughts Rexas Finance (RXS) stands out as a game-changer in the crypto market, seamlessly merging blockchain technology with traditional asset management. With $12.2 million raised and a presale price that has tripled since launch, it's clear that investors are recognizing its potential. As RXS continues its presale journey and prepares for market launch, it promises lucrative returns for early participants and a revolutionary platform for tokenizing real-world assets. With projections pointing toward double-digit prices by year-end, now is the time to join the RXS revolution. For more information about Rexas Finance (RXS) visit the links below: Website: https://rexas.com Win $1 Million Giveaway: https://bit.ly/Rexas1M Whitepaper: https://rexas.com/rexas-whitepaper.pdf Twitter/X: https://x.com/rexasfinance Telegram: https://t.me/rexasfinance Contact: Leo Gabriel pr@rexas.com Disclaimer: This content is provided by Rexas Finance . The statements, views and opinions expressed in this column are solely those of the content provider. The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities. Please conduct your own research and invest at your own risk . Photos accompanying this announcement are available at https://www.globenewswire.com/NewsRoom/AttachmentNg/2dd098e0-4db0-4207-88e8-b84c35103bb3 https://www.globenewswire.com/NewsRoom/AttachmentNg/3f36ecb6-a412-415d-814a-d02529bbbd1f © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Man City collapse ‘difficult to swallow’ – Pep Guardiola
Columbia, a perennial football loser, wins Ivy League title for first time since 1961NASSAU, Bahamas — It’s coming, slowly but methodically. Kadary Richmond is getting there. He’s showing glimpses of the dominant figure he was at Seton Hall. There was the more aggressive performance in a win over New Mexico, his clutch play to force multiple overtimes in the loss to No. 13 Baylor before cramps shut him down for the second extra session, and his efficient effort in the blowout of Virginia . “Starting to get comfortable picking my spots,” the 6-foot-6 lead guard said on Saturday, as St. John’s prepared to face Georgia on Sunday to end this challenging trip to The Bahamas. “I’m playing with a lot of talented guys who also have the ball in their hands, so just adjusting to that.” Over the last three games, Richmond is averaging 13.3 points, 5.3 assists, 4.6 rebounds and 2.3 steals, numbers more along the lines of how he performed a year ago. He’s been more assertive at both ends of the floor, not as passive as he was out of the gate, finding the right balance between getting his teammates involved and taking charge himself. “He’s one of one,” teammate Aaron Scott said. “He’s an All-American for a reason. Nobody can really guard him one-on-one. He makes everybody around him better. That’s what a point guard is supposed to do. “That’s Kadary — he’s going to step it up when it’s time to step it up.” This is obviously still new for the All-American — new teammates, new coaching staff, new school. He’s never been surrounded by so much talent at this level. Everything ran through him at Seton Hall. That doesn’t have to be the case for No. 22 St. John’s to be successful. He’s sharing ballhandling duties with another point guard, Deivon Smith, and sometimes is playing off the ball. “It was rough because we really didn’t get much practice reps together because we were switching teams and stuff,” Richmond said. “But once we kept it consistent and started playing with each other more, I feel it’s helping for all of us.” It remains an adjustment, along with his jump shot. Richmond is still working to get the hitch out of his shot. In practice, you don’t see it, but in games it has been there at times. He has attempted nine 3s so far, making three. “I’m about 40-50 percent with my mechanics, changing it,” he said. “I feel good about it though, it’s going well. I just have to get more attempts up. ... I try not to [revert back to my old form], but at times it happens. With more reps and more attempts, I think I’ll feel much more comfortable and [get] a lot more attempts and a lot more makes.” Overall, Richmond is pleased with St. John’s 5-1 start. They are further along at this point than he expected. The response to the Baylor loss was impressive , a sign of this group’s toughness when facing adversity. It has a chance to head home feeling really good about itself by beating Georgia on Sunday before a six-day break. “It’s a lot of fun, a lot of talented, high-flying guys, a lot of dunking going on, a lot of sharing the ball,” Richmond said. “We’re just showing we’re getting more comfortable playing together and we handled adversity well the other day with that tough loss to Baylor. We’re showing that we’re resilient and that we’re a pretty good team and we can play with anybody.”The idea for Egypt’s Chefaa pharmacy delivery app came from a very personal dilemma. When Doaa Aref was diagnosed with cancer in 2016 and needed surgery then ongoing treatment, she had to isolate herself after undergoing radioiodine therapy. Cut off from the outside world, she found she could order everything she needed online, with one crucial exception – she could not get the medicine she needed. “She called me to say she can literally order anything she needs online, except for the medication she was going to need for the rest of her life after the surgery,” recalls her friend and co-founder of the app, Dr Rasha Rady. Dr Rady told her she was not alone. “All my chronic patients were facing that,” she said. Egypt’s old-fashioned and fractured pharmacy network meant the market was not digitised. Inventory lists were not shared and were sometimes still kept on paper. It was difficult to tell what each pharmacy had on its shelves without popping in, so looking for a particular medicine might mean going door-to-door. The problem was the seed of an idea and seven years later, the pair’s app matches more than 2.1m active users with pharmacies that will send them the right medicine. They have raised $8.6m in funding and have also set up in Saudi Arabia. Dr Rady said: “Having a big gap can be seen as a challenge, or can be seen as an opportunity. We saw this as an opportunity. We have a huge gap in Africa and Egypt, when it comes to the data infrastructure. In the past five years, everything was paper and pen, it was not even digital.” Chefaa’s success is not isolated, say market analysts. While Africa may not share Silicon Valley’s reputation for start-ups, many countries do have a small, but driven set of digital entrepreneurs and innovators . , says Remi Adeseun, of Salient Advisory, a boutique consultancy firm looking at health tech in Africa that has identified 24 leading start-ups. Africa’s health systems have huge gaps and great shortages of funding, but new technology can open new ways to fill the holes, says Mr Adeseun, global director. He says: “Technology is very useful for bridging these kinds of gaps in that it can take one to many, where bricks and mortar are restricted to one to one.” “This is one of the advantages: the huge opportunity that exists in terms of unmet needs and the fact that there’s a crop of innovators who are socially driven but also see economic opportunity to solve these problems.” A sharp rise in the availability of internet and cheap Asian smartphones has also given a new mass-market platform. The World Bank estimates more than 160 million Africans gained broadband internet access between 2019 and 2022. The number of internet users in Sub-Saharan Africa more than doubled from 2016 to 2021. Between 2014 and 2021, nearly 200m started making or receiving digital payments. In Nigeria, in 2016, around a quarter of people were using the internet. By 2021, that was nearly a third. In Kenya it was nearly two-fifths and in Egypt nearly three-quarters. Then, just like in Europe and the US, the arrival of Covid-19 acted as another catalyst. Stuck at home, conservative consumers and businesses overnight had to overcome their suspicion of online commerce. Oghentega Iortim came up with the idea for his own health start-up in Nigeria, while running a horticulture venture. He said: “We quickly found that we were unable to sell fast enough before the plants died, as we were unable to store them in a controlled environment. Worse still, we were unable to find any storage facilities which would be able to meet our needs.” He and colleagues started looking at ways to monitor storage conditions, like the temperature they needed. He said: “This transformed into the idea of building something with this solution – and that it wouldn’t just be applicable in the agricultural sector.” The resulting start-up, Figorr, provides internet-linked sensors that monitor the temperature, humidity and location of delicate shipments of drugs, vaccines or equipment. Clients can track the conditions of their delicate consignments to stop losses as they move along supply chains. He said: “The problem I am trying to address is basically the problem of losses. When you look at Africa today, one of the things you hear over and over again is how many vaccines do not reach kids across the continent because of the lack of infrastructure, or the failure of infrastructure. “Say I am transporting vaccines that need to be stored at 2C to 8C and something has happened and temperatures are going way below or way above, we prompt users to take action to prevent losses from happening.” The business has been embraced by insurers, who are now prepared to underwrite shipments they previously thought were too risky to touch. Covid-19 was a boost for Figorr, after the fledgling company was brought in by the Nigerian government to try to stop losses in vaccines. Figorr has raised $1.5m of funding in Nigeria, Kenya, South Africa. “I wouldn’t say we’re well established, but we’re getting there,” he says. Many African countries have a pool of young, cheap, tech savvy developers who can in the early days. Early funding often comes from friends, family and local investors. But at a certain stage, when serious money is needed, African start-ups are still likely to need to find venture capital from America or Europe. Mr Adeseun said: “Venture capital is the lifeblood of scale. To a point, venture capital is not a charity, they are looking to make multiple returns on their investment. It is therefore very encouraging to see that of these leading innovators that we identified, almost half of them are funded from local investors.” Overall, Mr Adeseun says it is an exciting time to be in the market. He said: “Exciting as the times are, there are clear barriers. One of those barriers is capital, access to working, patient capital. The key thing is that until the access becomes more routine and mainstream, it’s going to be a challenge.”